Oppenheimer Thinks Oric Pharmaceuticals’ Stock is Going to Recover


Oppenheimer analyst Kevin DeGeeter maintained a Buy rating on Oric Pharmaceuticals (ORIC) yesterday and set a price target of $52.00. The company’s shares closed last Wednesday at $21.50, close to its 52-week low of $18.60.

According to TipRanks.com, DeGeeter is a top 100 analyst with an average return of 43.0% and a 52.2% success rate. DeGeeter covers the Healthcare sector, focusing on stocks such as Cyclacel Pharmaceuticals, Sensei Biotherapeutics, and Cellectar Biosciences.

Oric Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $50.33.

See today’s analyst top recommended stocks >>

The company has a one-year high of $40.81 and a one-year low of $18.60. Currently, Oric Pharmaceuticals has an average volume of 218.2K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely, ORIC-101 and ORIC-533.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts